Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
XOMAP
XOMAP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
XOMAP News
XOMA Royalty Corporation's Preferred Stock (XOMAP) Price Target Raised by 11.43% to 68.83
Dec 21 2025
NASDAQ.COM
XOMA Royalty Announces Financial Results for Q3 and Year-to-Date 2025, Along with Recent Business Milestones
Nov 12 2025
Newsfilter
XOMA Royalty Prolongs Tender Offer to Purchase LAVA Therapeutics N.V.
Oct 02 2025
Newsfilter
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
Aug 04 2025
Newsfilter
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
Aug 04 2025
Newsfilter
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
Jun 27 2025
Newsfilter
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Jun 18 2025
Newsfilter
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
May 27 2025
Newsfilter
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
May 13 2025
Newsfilter
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
Apr 14 2025
Newsfilter
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
Apr 02 2025
Newsfilter
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Mar 20 2025
Newsfilter
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Dec 19 2024
Newsfilter
XOMA Preferred Shares Series A declares $0.5391 dividend
Dec 19 2024
SeekingAlpha
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Nov 07 2024
Newsfilter
Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
Sep 23 2024
Newsfilter
Show More News
